Evidence map›Paper›PMID 37239109›Full record

ArticleBiomedicines2023

A Dysferlin Exon 32 Nonsense Mutant Mouse Model Shows Pathological Signs of Dysferlinopathy.

Océane Ballouhey, Marie Chapoton, Benedicte Alary, Sébastien Courrier, Nathalie Da Silva, Martin Krahn, Nicolas Lévy, Noah Weisleder, Marc Bartoli

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Restoration of Dysferlin After Exon 32 Skipping in Patient Cells.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Océane BallouheyAix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
Marie ChapotonAix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
Benedicte AlaryAix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
Sébastien CourrierAix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
Nathalie Da SilvaAix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
Martin KrahnAix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
Nicolas LévyAix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.
Noah WeislederDepartment of Physiology & Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.ORCID 0000-0003-2710-3088
Marc BartoliAix Marseille University, INSERM, MMG, U1251, 13005 Marseille, France.ORCID 0000-0003-3339-9858
Inserm · FRThe Ohio State University Wexner Medical Center · US

Funding

NIAMS NIH HHS R01-AG056504
6 · The paper itself

Abstract

Dysferlinopathies are a group of autosomal recessive muscular dystrophies caused by pathogenic variants in the DYSF gene. While several animal models of dysferlinopathy have been developed, most of them involve major disruptions of the Dysf gene locus that are not optimal for studying human dysferlinopathy, which is often caused by single nucleotide substitutions. In this study, the authors describe a new murine model of dysferlinopathy that carries a nonsense mutation in Dysf exon 32, which has been identified in several patients with dysferlinopathy. This mouse model, called Dysf

Indexed as

dysferlindystrophyLGMDR2

Identifiers

PMID37239109
PMCPMC10216094
OpenAlexW4376610830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.